Top

Published in:

Open Access 01-01-2015 | Original Article

Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition

Authors: Kazunari Ishii, Chisa Hosokawa, Tomoko Hyodo, Kenta Sakaguchi, Kimio Usami, Kenji Shimamoto, Makoto Hosono, Yuzuru Yamazoe, Takamichi Murakami

Published in: Annals of Nuclear Medicine | Issue 1/2015

Abstract

Purpose

There is evidence that some cases of patients with dementia with Lewy bodies (DLB) can demonstrate Alzheimer disease (AD) like reduced glucose metabolism without amyloid deposition. The aim of this study was to clarify whether regional hypometabolism is related to amyloid deposits in the DLB brain and measure the degree of regional hypometabolism.

Methods

Ten consecutive subjects with DLB and 10 AD patients who underwent both Pittsburgh compound B (PiB)-PET and ¹⁸F-fluoro-2-deoxyglucose (FDG)-PET were included in this study. Regional standardized uptake value ratio (SUVR)s normalised to cerebellar cortices were calculated in the FDG- and PiB-PET images.

Results

All AD patients and five DLB patients showed amyloid deposits (PiB positive). In the DLB group the parietotemporal and occipital metabolism were significantly lower than those in the AD group but there was no difference between the posterior cingulate hypometabolism between DLB and AD groups. There were no differences in regional glucose metabolism between PiB positive and negative DLB patients.

Conclusions

In the DLB brain, it is suggested that decreased regional glucose metabolism is unrelated to amyloid deposits, although the hypometabolic area overlaps with the AD hypometabolic area and the degree of parietotemporal and occipital hypometabolism in DLB brain is much larger than that in AD brain.

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.PubMedCrossRef

Warr L, Walker Z. Identification of biomarkers in Lewy-body disorders. Q J Nucl Med Mol Imaging. 2012;56:39–54.PubMed

Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology. 1998;51:125–30.PubMedCrossRef

Donaghy P, Thomas AJ, O’Brien JT. Amyloid PET Imaging in Lewy Body Disorders. Am J Geriatr Psychiatry. 2013 [Epub ahead of print].

Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging. 2012;33:2091–105.PubMedCentralPubMedCrossRef

Kantarci K, Yang C, Schneider JA, Senjem ML, Reyes DA, Lowe VJ, et al. Antemortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging. 2012;33:878–85.PubMedCentralPubMedCrossRef

Meyer PT, Frings L, Hellwig S. Update on SPECT and PET in parkinsonism—part 2: biomarker imaging of cognitive impairment in Lewy-body diseases. Curr Opin Neurol. 2014;27:398–404.PubMedCrossRef

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939–44.PubMedCrossRef

Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of ¹¹C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740–54.PubMedCrossRef

10.

Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The ¹⁸F-FDG PET cingulate island sign and comparison to ¹²³I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50:1638–45.PubMedCrossRef

11.

Shimada H, Shinotoh H, Hirano S, Miyoshi M, Sato K, Tanaka N, et al. beta-Amyloid in Lewy body disease is related to Alzheimer’s disease-like atrophy. Mov Disord. 2013;28:169–75.PubMedCrossRef

12.

Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71:903–10.PubMedCentralPubMedCrossRef

13.

Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009;34:107–12.PubMedCrossRef

14.

Brooks DJ. Imaging amyloid in Parkinson’s disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord. 2009;24(Suppl 2):S742–7.PubMedCrossRef

15.

Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [¹¹C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79:1331–8.PubMedCrossRef

16.

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718–25.PubMedCrossRef

17.

Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Marti MJ, et al. Confluence of alpha-synuclein, tau, and beta-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol. 2013;72:1203–12.PubMedCrossRef

Title: Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition
Authors: Kazunari Ishii
Chisa Hosokawa
Tomoko Hyodo
Kenta Sakaguchi
Kimio Usami
Kenji Shimamoto
Makoto Hosono
Yuzuru Yamazoe
Takamichi Murakami
Publication date: 01-01-2015
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 1/2015
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-014-0911-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells

68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs

Improvement in PET/CT image quality in overweight patients with PSF and TOF

Feasibility and performance of lymphoscintigraphy in sentinel lymph node biopsy for early cervical cancer: results of the prospective multicenter SENTICOL study

Evaluation of normality and reproducibility parameters of scintigraphy with 99mTc-MAA in the diagnosis of intrapulmonary vascular dilatations

Distribution of residual long-lived radioactivity in the inner concrete walls of a compact medical cyclotron vault room